Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IGSF11 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IGSF11 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. HEK293 Expressed. |
View IGSF11 Products |
| Gene Delivery | IGSF11 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based assays. |
View IGSF11 Products |
| Benchmark Ab | Anti-IGSF11 Recombinant Antibody Recombinant positive control for binding and blocking assays. |
View IGSF11 Products |
| Validator | IGSF11 siRNA Set For target knockdown validation and specificity verification. |
View IGSF11 Products |
| Related Target A | VISTA (VSIR) Primary receptor for IGSF11 (VSIG3). Crucial for blocking assay validation. |
View VISTA Products |
| Related Target B | PD-L1 Synergistic immune checkpoint. Often evaluated in combination therapies. |
View PD-L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cynomolgus/Mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE |
| Subfamily counter-screening (VSIG family off-targets) | Homolog panel proteins (VSIG1, VSIG2, VSIG4, VSIG8) strictly verified with native glycosylation profiles |
| Lack of reliable positive controls | Sequence-verified Clinical Benchmark Antibodies (Biosimilars) included in the catalog |
| False positives in cell binding | Sequence-verified siRNA pool included for target-specific knockdown validation |
Live IGSF11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IGSF11 (also known as VSIG3) therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and combination regimens. As first-generation therapies targeting the VISTA/IGSF11 pathway reach early clinical stages, the next wave of R&D is targeting the overcoming of cold tumor microenvironments through dual checkpoint blockade.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Immuno-oncology biotechs | Solid Tumors (Colorectal, Hepatocellular, Gastric) | Receptor-Ligand Blocking Assay (Need high-purity IGSF11 and VISTA ECD-Fc) |
| Bispecific Antibody | Global pharmaceutical developers | Cold Tumors, PD-1/PD-L1 Refractory Cancers | Dual-binding kinetics validation (Need stable HEK293-expressed proteins) |
| Cell Therapy (CAR-T/NK) | Academic and clinical institutes | Glioblastoma, Brain Metastases | Target expression verification (Need high-titer Lentivirus for stable cell lines) |